http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Apr 2026 01:41:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html <p>OSE Immunotherapeutics SA (Euronext: OSE) announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi in ovarian cancer will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.</p> <p>Dr. Alexandra Leary from Gustave Roussy and lead investigator of the TEDOVA trial will deliver the oral presentation on May 30 at 8:06 a.m. CDT. The presentation will cover results from the randomized trial evaluating the neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance treatment.</p> <p>The TEDOVA study is a three-arm Phase 2 trial involving http://www.streetinsider.com/FDA/OSE+Immunotherapeutics+to+present+ovarian+cancer+trial+results+at+ASCO/26353222.html Thu, 23 Apr 2026 01:41:19 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html <p align="justify"><b>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).</p> <p align="justify"><b>Alexandra Leary, MD, PhD</b>, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Announces+Presentation+of+TEDOVA+Phase+2+Topline+Results+of+Tedopi%C2%AE+in+Ovarian+Cancer+at+the+ASCO+2026+Meeting/26353220.html Thu, 23 Apr 2026 01:30:00 -0400 A.50216726 A.50216777 O.01678312 O.21612337 O.54516537 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html <p align="center"><b>OSE Immunotherapeutics Evolves its Leadership Team</b></p> <p align="center">Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively</p> <p align="justify"><b><br/>Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company is further enhancing its Executive team by appointing Thomas Gidoin as Deputy Chief Executive Officer (<i>Directeur Général Adjoint</i>) and Aurore Morello as Chief Scientific Officer. These appointments reflect http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Evolves+its+Leadership+Team/26310774.html Tue, 14 Apr 2026 12:00:00 -0400 A.26800952 A.32727947 O.00048394 O.00711722 O.01678312 OSE